Nuformix plc
("Nuformix" or "the Company")
Advisory Panel Appointments
Chaired by Dr Andy Richards
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces the following appointments to its Advisory Panel, with immediate effect:
Dr Andy Richards CBE - appointed Chairman, Advisory Panel. Andy is Chairman of Congenica, Arecor, and Abcodia, and is a director of Silence Therapeutics plc, Ieso Digital Health, Sensiia, and Cancer Research Technology (commercial arm of CR-UK). He is Chair of the Babraham Research Campus and was until recently a non-executive director of Cambridge University Hospitals Trust.
His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience. Since 1999 he has founded, invested in and helped to scale innovative UK based biotechnology and healthcare companies, with more than 25 ventures over the last 16 years. These include companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels, and was awarded a CBE in 2015 for services to life-science investment.
Prof Derek Mann - Nuformix has been working with Derek and his team to further validate NFX002, the Nuformix fibrosis programme. Derek will continue to advise the Nuformix team in pre-clinical fibrosis research.
He is Director of the Newcastle Fibrosis Research Group (NFRG), which is focussed on developing translational solutions to tissue remodelling and scar formation in the liver, lung, kidneys, heart and skin. Derek's research group is primarily interested in understanding the molecular basis for liver fibrosis (scarring) and primary liver cancer. Recent discoveries include mechanisms of transgenerational epigenetic inheritance affecting fibrosis and a role for inflammatory neutrophils in hepatocellular carcinoma.
At the NFRG he has developed a number of collaborative strategic alliances with major pharmaceutical companies including GSK and Abbvie, which are aimed at translation of the NFRG research to the design of fibrosis biomarkers and new therapeutics. He is also the Dean of Research and Innovation in the Faculty of Medical Sciences at Newcastle University.
Dr Paul Goldsmith - Paul joins the Advisory Panel. He is a commercial medic with experience founding and building both drug and digital health companies and is now co-leading the development of Closed Loop Medicine Ltd. He is a Consultant Neurologist, trained in Cambridge, Oxford, London and Newcastle. His insights into the translational clinical-commercial interface will be invaluable to Nuformix.
Commenting, Dr Andy Richards, said: "Co-crystallisation is a broadly applicable technology with much promise for modulating, improving and differentiating the properties of both new and known drug molecules. Nuformix is a world leader in the application of this approach, with a proven track record. I am excited about working with the team and with the Advisory Panel to further product developments that can benefit patients."
Commenting, Dr Dan Gooding, Chief Executive Officer, Nuformix, said: "Cementing our Advisory Panel was a key business objective post RTO-completion. This World-class team offers specific expertise relating to the delivery of key NFX activities and will evolve as the Company progresses. We've worked with Andy Richards for several years - it's difficult to find anyone more experienced in understanding the technical and commercial challenges in developing and commercialising products based on known drugs. We've also been working with Derek Mann and his NFRG team - currently one of the World's leading centres for conducting fibrosis research. Derek will guide us as we perform innovative, close-to-patient studies as we prepare to take NXP002 into the clinic. Paul Goldsmith brings invaluable experience of the real world clinical-commercial interface, in the context of the needs of a company such as Nuformix. Chaired by Dr Andy Richards, the Advisory Panel provides us with a wealth of technical and commercial understanding alongside corporate experience."
Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.
ENDS
Enquiries:
Nuformix plc Dr Dan Gooding, Chief Executive Officer |
+44 (0)1223 423667 |
Beaufort Securities Limited (Broker) Jon Belliss |
+44 (0)20 7382 8300 |
Gable Communications Ltd John Bick / Justine James |
+44 (0)20 7193 7463 |
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
